Suppr超能文献

mRNA 疫苗接种第三剂后对 SARS-CoV-2 奥密克戎亚变体的刺突识别和中和

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine.

机构信息

Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.

Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.

出版信息

Cell Rep. 2023 Jan 31;42(1):111998. doi: 10.1016/j.celrep.2023.111998. Epub 2023 Jan 9.

Abstract

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants have recently emerged, becoming the dominant circulating strains in many countries. These variants contain a large number of mutations in their spike glycoprotein, raising concerns about vaccine efficacy. In this study, we evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA vaccine to recognize and neutralize these Omicron subvariant spikes. We observed that BA.4/5 and BQ.1.1 spikes are markedly less recognized and neutralized compared with the D614G and other Omicron subvariant spikes tested. Also, individuals who have been infected before or after vaccination present better humoral responses than SARS-CoV-2-naive vaccinated individuals, thus indicating that hybrid immunity generates better humoral responses against these subvariants.

摘要

几种严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)奥密克戎亚变种最近出现,成为许多国家的主要流行株。这些变体在其刺突糖蛋白中含有大量突变,引起了对疫苗效力的关注。在这项研究中,我们评估了接受三剂 mRNA 疫苗的个体血浆识别和中和这些奥密克戎亚变体刺突的能力。我们观察到,与测试的 D614G 和其他奥密克戎亚变体刺突相比,BA.4/5 和 BQ.1.1 刺突的识别和中和能力明显降低。此外,与 SARS-CoV-2 无感染史的接种个体相比,接种前或接种后感染过的个体产生了更好的体液免疫反应,这表明混合免疫对这些亚变体产生了更好的体液免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9139/9826988/b7a43f77d336/fx1_lrg.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验